Division of Head & Neck and Mammary Oncology, Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China.
Contemp Clin Trials. 2011 Sep;32(5):649-53. doi: 10.1016/j.cct.2011.04.015. Epub 2011 May 5.
This study aimed to assess the attitudes of oncology physicians and nurses toward phase I, II, and III cancer clinical trials.
A questionnaire was administered to 358 oncology physicians and nurses.
The effective response rate was 79.3%. Of the respondents, 67.6%, 95.1%, and 98.6% reported that cancer patients would benefit from phase I, II, and III trials, respectively. Respondents would also recommend that their patients participate in phase I (64.4%), II (88.4%), and III trials (95.1%). When asked to assume the role of cancer patients, the respondents themselves were willing to participate in phase I (48.2%), II (72.9%), and III trials (89.8%). Respondents who admitted having little or no understanding of cancer clinical trials were not willing to recommend participation in phase I clinical trials to their patients (OR 0.187, 95% CI 0.110-0.319, p<0.001). No factor was significantly associated with respondents' willingness to recommend that their patients participate in phase II or III clinical trials.
Most physicians and nurses hold positive attitudes toward clinical trials, especially phases II and III. The number of medical staff who approved of clinical trials was positively associated with the stage of the phase trial.
本研究旨在评估肿瘤医师和护士对 I 期、II 期和 III 期癌症临床试验的态度。
对 358 名肿瘤医师和护士进行问卷调查。
有效应答率为 79.3%。在受访者中，分别有 67.6%、95.1%和 98.6%报告称癌症患者将从 I 期、II 期和 III 期试验中受益。受访者还将推荐其患者参加 I 期（64.4%）、II 期（88.4%）和 III 期（95.1%）试验。当被要求假设为癌症患者时，受访者自己愿意参加 I 期（48.2%）、II 期（72.9%）和 III 期（89.8%）试验。承认对癌症临床试验了解甚少或不了解的受访者不愿意向其患者推荐参加 I 期临床试验（OR 0.187，95%CI 0.110-0.319，p<0.001）。没有任何因素与受访者愿意推荐其患者参加 II 期或 III 期临床试验显著相关。
大多数医师和护士对临床试验持有积极的态度，尤其是对 II 期和 III 期临床试验。认可临床试验的医务人员数量与临床试验的阶段呈正相关。
